Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309075 | 1.00 | PARP1 (0.52) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL4312622 | 1.00 | PARP1 (0.52) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL7985625 | 0.92 | PARP1 (0.49) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL5224952 | 0.92 | PARP1 (0.50) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL5224956 | 0.92 | PARP1 (0.50) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL18129846 | 0.92 | PARP1 (0.50) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL6110934 | 0.91 | PARP1 (0.49) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL4856306 | 0.89 | PARP1 (0.52) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL1283375 | 0.89 | PARP1 (0.52) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL8117710 | 0.89 | PARP1 (0.52) | PARP1ATMCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4310091-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| CN-106715413-A | Piperazine derivatives as liver x receptor modulators | 生命医药公司 | 2017-05-24 | — | — | CN | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-2791130-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8883789-B2 | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20130158042-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-7601728-B2 | Bicyclic pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | PARP1 985/4885ATM 4467/4885CA1 1194/4885 |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | PARP1 847/4885ATM 4215/4885CA1 1451/4885 |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | PARP1 847/4885ATM 4215/4885CA1 1451/4885 |
| US-20130158042-A1 | NOVEL COMPOUNDS | GRM5, GRIK5, GRM1 | PARP1 4420/4885ATM 2772/4885CA1 2549/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | PARP1 1602/4885ATM 3256/4885CA1 1372/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | PARP1 1121/4885ATM 190/4885CA1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.